Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.38 |
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582784 | 1.00 | POLB (0.43) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL582583 | 0.95 | NR3C1 (0.48) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1471299 | 0.95 | NR3C1 (0.48) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1471871 | 0.84 | POLB (0.45) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL582832 | 0.79 | NR3C1 (0.51) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL583104 | 0.77 | POLB (0.56) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL583870 | 0.72 | NR3C1 (0.60) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL583364 | 0.72 | POLB (0.78) | POLBNR3C1PDE4BLMNASMN1; SMN2 | |
| SCHEMBL582367 | 0.71 | POLB (0.53) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL583577 | 0.70 | PDE4B (0.54) | PDE4BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-28 | — | — | US | disclosed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | POLB 1725/4885NR3C1 519/4885PDE4B 5/4885 |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE4B, PDE4A, PDE3B | POLB 749/4885NR3C1 3791/4885PDE4B 1/4885 |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4B, PDE3A | POLB 775/4885NR3C1 3658/4885PDE4B 2/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | POLB 1829/4885NR3C1 690/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.